)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
CytoMed Therapeutics (GDTC) investor relations material
CytoMed Therapeutics H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary2 Oct, 2025
Executive summary
Revenue for the six months ended June 30, 2025, increased to $156,000 (S$155,887), driven by new private banking and cord blood banking services in Malaysia following asset acquisition.
Net loss for the period was $2,050,000 (S$2,245,828), or $0.19 (S$0.19) per share, with higher research, share-based payments, and other expenses.
Clinical-stage biopharma focused on allogeneic, off-the-shelf cell-based immunotherapies for cancer and degenerative diseases, with four product candidates in development.
Phase 1 trial for lead candidate CTM-N2D is underway in Singapore, with completion targeted for 2026.
Asset acquisition in Malaysia enabled first revenue from private blood banking.
Financial highlights
Revenue for H1 2025 was $156,000 (S$155,887), primarily from private and cord blood banking services.
Net loss widened to $2,050,000 (S$2,245,828), driven by higher research, share-based payments, and other expenses.
Cash and bank balances declined from $4,970,000 (S$4.97 million) at December 31, 2024, to $2,860,000 (S$2.85 million) at June 30, 2025.
Operating cash outflow increased to S$1.6 million from S$1.16 million year-over-year.
Other operating income decreased by 8.5% year-over-year, mainly due to lower interest income from IPO proceeds.
Outlook and guidance
Management expects current resources and proceeds from recent and potential equity offerings to be sufficient for at least the next 12 months.
Ongoing ATM equity program allows up to $4.3 million in new share sales to support liquidity.
Phase 1 clinical trial for CTM project in Singapore is ongoing, with completion targeted for 2026.
Preclinical and IND application progress continues for other pipeline projects, with international collaborations and income potential.
Collaboration with MD Anderson Cancer Center on preclinical studies for lymphoma published in a peer-reviewed journal in September 2025.
How will ATM agreement impact cash runway?
Revenue growth outlook for LongevityBank?
Next steps for CTM-GDT clinical trials?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next CytoMed Therapeutics earnings date
H2 202527 Apr, 2026
Next CytoMed Therapeutics earnings date
H2 202527 Apr, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
CytoMed Therapeutics Limited is a biotechnology company focused on developing cell-based immunotherapies for cancer treatment. The company leverages advanced cellular technology to create novel therapeutic solutions that harness the immune system’s capabilities to target and eliminate cancer cells. CytoMed's research and development efforts concentrate on proprietary cell therapy platforms that aim to offer effective, potentially less toxic alternatives to conventional cancer treatments. CytoMed Therapeutics Limited is headquartered in Singapore, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage